Bayer (BAYRY)
(Delayed Data from OTC)
$6.95 USD
-0.06 (-0.86%)
Updated Jun 26, 2024 03:59 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
BAYRY 6.95 -0.06(-0.86%)
Will BAYRY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BAYRY
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
Other News for BAYRY
Covestro unveils cost cuts amid UAE energy firm takeover talks
Warning: BAYRY is at high risk of cutting its dividend
Ocular Therapeutix jumps after investor day updates
Archer Daniels, Bayer extend farming collaboration
AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes